IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:08:28 2024-05-24 am EDT			5-day change	1st Jan Change
14.6 ^HKD	+2.82%		+0.69%	-51.17%

May. 17	Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China	MT
May. 17	Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	CI

ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma

November 19, 2023 at 11:23 pm EST

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that the first patient has been successfully dosed in the Phase II clinical trial of IMM2510 for the treatment of refractory or relapsed alveolar soft part sarcoma (ASPS).

Latest news about ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China	May. 17	MT
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	May. 17	CI
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	Apr. 17	MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	Apr. 17	CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	Mar. 26	MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Immuneonco Biopharmaceuticals CFO Resigns	Mar. 03	MT
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes	Mar. 01	CI
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug	Nov. 20	MT
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	Nov. 19	CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination	Nov. 09	MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug	Nov. 07	MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	Nov. 07	CI
ImmuneOnco to Present Results of Anti-Cancer Drug Studies at American Convention	Nov. 06	MT
China Grants Investigational New Drug Approval to ImmuneOnco's Cancer Treatment; Shares Fall 4%	23-10-16	MT
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16	CI
ImmuneOnco to Raise Near HK$17 Million from Over-Allotment of Shares	23-09-29	MT
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27	CI
ImmuneOnco Biopharma Completes Patient Enrollment for Phase 1 Study of Two Antitumor Medications	23-09-12	MT
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11	CI
Hong Kong Stocks Retreat On Fears Over China Property Default; ImmuneOnco Biopharmaceuticals Gains 5%	23-09-05	MT
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04	CI
ImmuneOnco Biopharmaceuticals Raises HK$234.5 Million in Hong Kong IPO	23-09-03	MT

Chart ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Duration

Period

Chart ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

More charts

Company Profile

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Ratings for ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

13.53 CNY

Average target price

15.13 CNY

Spread / Average Target

+11.81%

Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.	-51.17%	699M
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs